The 'ChatGPT for doctors,' OpenEvidence, was valued at $15 billion in a new funding round

Recent reporting across multiple digital publications details a significant financial milestone for OpenEvidence, an artificial intelligence platform frequently characterized in media reports as a ChatGPT for doctors. According to coverage from outlets including Business Insider, Axios, Livemint, and TradingView, the medical search platform has secured a $250 million alternative financing round. This substantial capital injection places the overall valuation of OpenEvidence at $15 billion. Additional reporting from healthcare.digital, Refresh Miami, and Digital Health Wire emphasizes the structural nature of this latest funding event.

The financing round was led by Andreessen Horowitz and Byers Capital. Beyond the headline figures, several publications draw attention to the broader strategic trajectory of the company. Specifically, coverage from Refresh Miami and Digital Health Wire notes that the enterprise is executing a pivot, moving its ambitions far beyond standard medical search capabilities. The context surrounding this funding event involves the rapid rise of specialized artificial intelligence applications tailored for professional industries.

As highlighted by Livemint and Business Insider, the platform has gained notable recognition within the medical sector for its utility, earning descriptive monikers that compare its conversational interface and information retrieval capabilities to mainstream generative artificial intelligence tools like ChatGPT. As the company absorbs this $250 million round led by Andreessen Horowitz and Byers Capital, observers and industry analysts will be watching to see how the platform deploys its capital. Coverage does not yet specify the exact operational milestones or product releases that will accompany this quiet raise and loud strategic pivot into broader medical and technological applications.